Look at Complete Prescribing Information and facts OPDIVO® (nivolumab) is indicated to the treatment of adult patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed just after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or following three or maybe more traces of systemic therapy that i